Clinical Trials Logo
  1. Home
  2. Acute Heart Failure
  3. NCT03234647
  4. Details
NCT03234647 Clinical Trial

First In Human Study of the Doraya Catheter for the Treatment of AHF Patients

Acute Heart Failure Clinical Trial

Official title:
First In Human Study of the Doraya Catheter for the Treatment of AHF Patients

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03234647
Other study ID # Doraya FIH Study for AHF
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2018
Est. completion date April 30, 2021

Study information
Verified date September 2018
Source Revamp Medical Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Safety and performance evaluation of the Doraya catheter in patients admitted with AHF.

Description:

The purpose of this clinical investigation is to evaluate the safety and performance of the Doraya catheter in patients admitted with AHF, presenting persistent volume over load and poor response to diuretic treatment.

Recruitment information / eligibility
Status Completed
Enrollment 9
Est. completion date April 30, 2021
Est. primary completion date April 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - AHF subjects with poor diuretic response Exclusion Criteria: - AHF subjects with sufficient diuretic response

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• Doraya catheter
Temporary deployment of the Doraya catheter in AHF patients.

Locations
Country Name City State
Belgium Onze-Lieve-Vrouwziekenhuis Aalst Aalst
Belgium ZNA Middelheim Antwerpen
Israel Rambam Health Care Campus Haifa
Israel Shaare Zedek Medical Center Jerusalem
Poland Slaski Uniwersytet Medyczny w Katowicach Katowice
Poland 4th Military Wroclaw
Poland University Hospital Wroclaw

Sponsors (1)
Lead Sponsor Collaborator
Revamp Medical Ltd.

Countries where clinical trial is conducted

Belgium,  Israel,  Poland, 

Outcome
Type Measure Description Time frame Safety issue
Primary Device or procedure related Serious Adverse Event (SAE) rate through 60 days SAE as defined by ISO 14155 60 days
See also
  Status Clinical Trial Phase
Terminated NCT02151383 - Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure Phase 2
Completed NCT02135835 - A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure Phase 4
Recruiting NCT05556044 - Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction Phase 3
Recruiting NCT04363697 - Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68) Phase 4
Completed NCT02122640 - Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department N/A
Completed NCT01193998 - Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department N/A
Not yet recruiting NCT01211886 - Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU) N/A
Not yet recruiting NCT06465498 - Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography N/A
Recruiting NCT05276219 - Optimized Treatment of Pulmonary Edema or Congestion Phase 4
Recruiting NCT05392764 - Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure Phase 3
Recruiting NCT03157219 - Manipal Heart Failure Registry (MHFR) N/A
Completed NCT06024889 - Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure. Phase 1/Phase 2
Terminated NCT04174794 - Investigating Reduction of aCute heArt Failure Readmission With Lung UltraSound-preliminary Trial
Recruiting NCT05972746 - Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure N/A
Enrolling by invitation NCT02258984 - Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial N/A
Completed NCT02141607 - Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock
Completed NCT01870778 - Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF Phase 3
Recruiting NCT05986773 - Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance Phase 4
Recruiting NCT04163588 - Sequential Nephron Blockade in Acute Heart Failure Phase 3
Recruiting NCT03720288 - Acetazolamide in Patients With Acute Heart Failure Phase 3